Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

A team of researchers has developed a novel therapy that could be effective for different types of cancers. The study, published in the journal <keyword id="2533828" type="ORGANIZATION" weightage="20" keywordseo="Cancer-Discovery">Cancer Discovery</keyword>, indicates that the therapeutic agent shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive. "Translating these findings into effective cancer therapies for patients is a high priority...," said researcher <keyword id="11715894" type="UNKNOWN" weightage="20" keywordseo="jian-jin">Jian Jin</keyword> from Mount Sinai in the US. According to the researchers, the therapy is an engineered molecule, MS21, that causes the degradation of <keyword id="2444122" type="PERSON" weightage="20" keywordseo="Akt">AKT</keyword>, an enzyme that is overly active in many cancers. This study laid out evidence that pharmacological degradation of AKT is a viable treatment for cancers with mutations in certain genes, the researchers said. AKT is a cancer gene that encodes an enzyme that is frequently abnormally activated in cancer cells to stimulate tumor growth. Degradation of AKT reverses these processes and inhibits tumor growth. "Our study lays a solid foundation for the clinical development of an AKT degrader for the treatment of human cancers with certain gene mutations," said co-author <keyword id="11715895" type="UNKNOWN" weightage="20" keywordseo="ramon-parsons">Ramon Parsons</keyword> from the varsity. "Examination of 44,000 human cancers identified that 19 per cent of tumours have at least one of these mutations, suggesting that a large population of cancer patients could benefit from therapy with an AKT degrader such as MS21," <keyword id="1664191" type="PERSON" weightage="20" keywordseo="Ramon">Ramon</keyword> added. MS21 was tested in human cancer-derived cell lines, which are models used in laboratories to study the efficacy of cancer therapies. The researchers are looking to develop MS21 with an industry partner to open clinical trials for patients. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/news/amazon-prime-day-2021-best-deals-on-gaming-laptops-keyboards-and-more/articleshow/84701404.cms">Amazon Prime Day 2021: Best deals on gaming laptops, keyboards and more</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/retail/news/reliance-retail-surprises-all-by-more-than-doubling-its-net-profit-in-the-last-three-months/articleshow/84680413.cms">Reliance Retail surprises all by more than doubling its net profit in the last three months</a>

Novel therapy might be effective for different types of cancers, according to study

You Searched For "ramon parsons" and got 1 results

Novel therapy might be effective for different types of cancers, according to study

IANS

Popular Keywords

Buying Guides